- Supported exchanges /
- KQ /
- 365270.KQ
Curacle Co. Ltd. (365270 KQ) stock market data APIs
Curacle Co., Ltd., a bio-venture business, engages in the research and development of drugs for diseases caused by aging process and damage to blood vessels. Its products cover age-related vascular diseases, intractable metabolic diseases, and cancer targeting/immunotherapy. The company's products in pipeline include CU06, which covers treatment and medical indications, such as diabetic macular edema/retinopathy, acute respiratory distress syndrome, myocardial infarction, stroke treatment, concomitantly used with immunotherapy, inflammatory bowel disease treatment, and hereditary angioedema; CU03, which is in Phase 2a clinical trial study for the treatment of age-related macular degeneration; and CU01, a diabetic nephropathy medicine that completed Phase 2a clinical trial. Its products in back-up pipeline include CU02, a product for nonalcoholic steatohepatitis treatment; CU04, a product for the treatment of cancer (c-Myc inhibitor); and CU05, a product for the treatment of cancer (Amigo2-PDK1 inhibitor). The company was founded in 2016 and is based in Seoul, South Korea.
Curacle Co. Ltd. Financial Data Overview
| 6000 | |
| 6080 | |
| - | |
| 6140 | |
| 5950 | |
| 4900-21350 | |
| 83 244 M | |
| 13 874 K | |
| 4 038 M | |
| -301.3485 | |
| 1.514 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Curacle Co. Ltd. Fundamental Data is available in our Financial Data APIs
- Net Revenue 4 038 M
- EBITDA -14 010 836 992
- Earnings Per Share
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Curacle Co. Ltd. Earnings via APIs
- Latest Release 2024-09-30
- EPS/Forecast NaN
Get Curacle Co. Ltd. End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
